39893-50-0Relevant academic research and scientific papers
COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
-
Paragraph 0503-0504, (2018/07/04)
The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
-
Paragraph 0225, (2018/10/19)
The present invention provides modulators of protein function, to restore protein homeostasis, including GSPT1 activity. The invention provides methods of modulating protein-mediated diseases, such as GSPT1-mediated diseases, disorders, conditions, or responses. Compositions are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as GSPT1-mediated diseases, disorders, and conditions, including cancer and astrogliosis.
DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS
-
Page/Page column 65, (2011/05/06)
The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
NOVEL HETEROCYCLYL COMPOUNDS
-
Page/Page column 28, (2011/05/03)
The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.
Pyrazolines as insecticides
-
, (2008/06/13)
Novel pyrazolines of the formula (I) wherein A represents a phenyl group which may be substituted by at least one substituent selected from the class consisting of halogen, C1 4alkyl, C1 4alkoxy and halogeno-C1 4alkyl, or A represents halogen-substituted 3-pyridyl,B represents phenyl which may be substituted by halogen, or B represents halogen substituted 3-pyridyl,X represents hydrogen, halogen or halogeno C1 4alkyl, and, Y represents hydrogen, halogen, C1 4alkyl or halogeno-C1 4alkyl, with the proviso that X and Y do not simultaneously represent hydrogen atom, and that at least one of A and B represents halogen-substituted 3-pyridyl. The new compounds exhibit powerful insecticidal properties.
